Skip to content

Inpatient Blood Glucose Control in Taichung Veterans General Hospital

The Effects of Glucose Control and Monitor on Inflammation in the Hospitalized Patients With Hyperglycemia

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02885909
Enrollment
600
Registered
2016-09-01
Start date
2016-09-30
Completion date
2025-12-31
Last updated
2020-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HYPERGLYCEMIA

Keywords

type 2 diabetes, inpatient, glucose control, continue glucose monitor

Brief summary

This study will be conducted in the ward of Taichung Veterans General Hospital. The patient with hyperglycemia in hospitalization will be enrolled by glucose management team.

Detailed description

This study will be conducted in the ward of Taichung Veterans General Hospital. The type 2 diabetic patient with hyperglycemia in hospitalization are candidates. The glucose will be controlled using the insulin protocal based on the glucose monitor systems. We will assess the effects of insulin protocal and glucose monitor system on the inpatient with hyperglycemia.

Interventions

DEVICECONTINUE GLUCOSE MONITOR

Continue glucose monitor

PROCEDUREInsulin protocal

Using insulin protocal based on glucose monitor

Sponsors

Taichung Veterans General Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Type 2 diabetic inpatient * Fasting glucose \>140 mg/dl or random glucose \>180 mg/dl

Exclusion criteria

* incooperative for glucose monitor * refusal of insulin * pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Glucose target6 daysThe ratio of glucose less than 180 mg/dl

Secondary

MeasureTime frameDescription
Fasting glucose target6 daysthe ratio of fasting glucose less than 140 mg/dl
Hypoglycemiatimessymptoms or less than 70
Vascular Cell Adhesion Molecule 1 (VCAM-1)6 daysInflammation
Brain-Derived Neurotrophic Factor (BDNF)6 daysPsychological assessment
Orexin-A6 daysPsychological assessment

Countries

Taiwan

Contacts

Primary ContactI-Te Lee, MD, PhD
itlee@vghtc.gov.tw+886-4-23592525

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026